What is ONCO's earnings growth forecast for 2025-2025?
(NASDAQ: ONCO) Onconetix's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Onconetix's earnings in 2025 is -$45,889,073.
In 2025, ONCO is forecast to generate -$1,560,852 in earnings, with the lowest earnings forecast at -$1,499,642 and the highest earnings forecast at -$1,606,759.
What is ONCO's revenue growth forecast for 2025-2025?
(NASDAQ: ONCO) Onconetix's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Onconetix's revenue in 2025 is $1,326,959.
In 2025, ONCO is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.
What is ONCO's forecast return on assets (ROA) for 2025-2025?
(NASDAQ: ONCO) forecast ROA is -8.16%, which is lower than the forecast US Biotechnology industry average of 12.84%.
What is ONCO's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: ONCO) Onconetix's current Earnings Per Share (EPS) is $959.99. In 2025, ONCO's EPS is forecast to hit -$1.01 (min: -$0.97, max: -$1.04).
What is ONCO's forecast return on equity (ROE) for 2025-2025?
(NASDAQ: ONCO) forecast ROE is -26.41%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.